Puration (PURA): Waiting For The Market To Find Out Its Got A U.S. Patent Maybe Even Better Than GW Pharm's (GWPH)
Puration, Inc. (PURA) has been working on reinventing itself for almost a year and it looks about ready to meet a few major milestones. If you’ve watched the progress of GW Pharmaceuticals (GWPH) – the PPS double recently to over $80 a share on news of a cannabis patent - and wish you’d gotten in earlier, or found a GWPH available for pennies instead of dollars, PURA might be what you’re looking for.
Yes, PURA is reinventing itself in the Cannabis sector. And yes, the cannabis sector has attracted a number of entrepreneurs over the last two to three years. And yes, it’s hard to tell the genuine entrepreneurial companies from the Johnny-come-lately-stock-jockeys looking to hang out a marijuana shingle in an attempt to take advantage of the dotcom like enthusiasm for the emerging legal status of the industry. But, by all counts, PURA looks to be one of the ‘real-ones.’
In July last year, PURA acquired an early stage cannabis operation from North American Cannabis Holdings (USMJ). USMJ, for lack of a better term, appears to be an ‘incubator’ in the cannabis sector. USMJ and PURA entered into an agreement to put one of USMJ’s cannabis incubation projects into Puration. The operation in Puration looks to have some legs.
Last week, the promise-of-the-PURA-investment-opportunity snuck into a press release published by USMJ. The press release was about the U.S. Patent awarded for the process to extract botanicals from cannabis – both marijuana and hemp. While USMJ published the press release, the Patent is actually in PURA (look carefully for this info in the 4th paragraph of the press release). Remember what happed to GWPH on its Patent news. Sooner or later PURA’s bound to publish its own press release on the Patent.
USMJ’s press release was part of a series or press releases USMJ made last week celebrating 420 week. The operation PURA acquired from USMJ is where the Patent resides through a JV with a not-for-profit called Nature’s Comfort Meds. USMJ partnered last year with Nature’s Comfort Meds in one of USMJ’s incubation projects to commercialize the Nature’s Comfort Meds technology. Shorty after the partnership initiated, Nature’s Comfort Meds was awarded a Patent for its technology. Again, that Patent is now under PURA and PURA now has something comparable to $80 per share GWPH.
Few OTC companies are ever going to succeed long-term and PURA has no greater chance of long-term success than any other OTC company. The ROI opportunity here doesn’t depend on a long-term success. PURA stock is available right now under $0.05. The issued and outstanding is only 50 million shares. If PURA can get its financials current with OTC Market Standard requirements and achieve one or two business milestones in the development of a commercialized use of the extraction Patent, then the PURA PPS has the potential to fly.
$1.00 is probably not out of the question, but with only 50,000 issued and out, even if the company takes that to 1 million issued and out over the next few months raising funds for development, the PPS has a much better chance of heading north somewhere than it does going south. Getting in now on PURA is almost a certain near term money making opportunity as long as the management team executes. So the bet is on the management team. Will they get the company current and hit one or two business development milestones? That doesn’t really seem to be too tall an order. This Wolf Wrangler is all-in on PURA.